What were Abbott India Ltd's latest quarterly results?
Abbott India Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +4.2%
- Revenue Growth YoY: +6.8%
- Operating Margin: 27.0%
Abbott India Ltd (Pharma - MNC bulk Drugs) — fundamental analysis, earnings data, and key metrics. PE: 36.4. ROE: 35.7%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Abbott India Ltd's latest quarterly results (Dec 2025) show
Abbott India Ltd's current PE ratio is 36.4x.
Abbott India Ltd's price-to-book ratio is 13.8x.
Abbott India Ltd's fundamental strength based on key financial ratios
Abbott India Ltd has a debt-to-equity ratio of N/A.
Abbott India Ltd's return ratios over recent years
Abbott India Ltd's operating cash flow is positive (FY2025).
Abbott India Ltd's current dividend yield is 1.82%.
Abbott India Ltd's shareholding pattern (Dec 2025)
Abbott India Ltd's promoter holding has remained stable recently.
Abbott India Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Abbott India Ltd may be worth studying
Abbott India Ltd investment thesis summary:
Abbott India Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.